{
  "meta": {
    "title": "42_Second_Line_Drugs_For_Tuberculosis",
    "url": "https://brainandscalpel.vercel.app/42-second-line-drugs-for-tuberculosis-df140282.html",
    "scrapedAt": "2025-11-30T12:34:27.646Z"
  },
  "questions": [
    {
      "text": "Which of the following drugs is not hepatotoxic?",
      "choices": [
        {
          "id": 1,
          "text": "Pyrazinamide"
        },
        {
          "id": 2,
          "text": "Isoniazid"
        },
        {
          "id": 3,
          "text": "Cycloserine"
        },
        {
          "id": 4,
          "text": "Ethionamide"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Cycloserine </strong>is not a hepatotoxic drug. The<strong> adverse effects </strong>of cycloserine are mainly<strong> neurological</strong>.</p>\n<p>Half of the patients on cycloserine (1g/day) experience neuropsychiatric symptoms. It ranges from headaches to psychosis, seizures, and suicidal ideas. Therefore, cycloserine is <strong>contraindicated</strong> in patients with <strong>epilepsy</strong>.</p>\n<p>Ethionamide, rifampicin, isoniazid and pyrazinamide are hepatotoxic agents. They are either contraindicated or used with extreme caution in hepatitis.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB7799",
      "difficulty": "medium"
    },
    {
      "text": "A 24-year-old woman who was started on treatment for MDR-TB 6 months back, presented with complaints of fatigue, amenorrhea, and constipation since the past 1 month. On examination, a swelling was noticed on the anterior aspect of her neck. Her lab reports show raised TSH levels with low free T3 and T4 levels. Which anti-tubercular drug is likely to cause this adverse effect?",
      "choices": [
        {
          "id": 1,
          "text": "Streptomycin"
        },
        {
          "id": 2,
          "text": "Pyrazinamide"
        },
        {
          "id": 3,
          "text": "Cycloserine"
        },
        {
          "id": 4,
          "text": "Ethionamide"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The given clinical features and lab reports are suggestive of<strong>&nbsp;hypothyroidism with goiter,</strong> which is a known adverse effect of<strong> ethionamide.</strong></p>\n<p>MDR-TB is treated with 2<sup>nd</sup>&nbsp;line agents that include ethionamide (ETH). ETH is not a first-line agent due to its gastrointestinal side effects. It&nbsp;is&nbsp;<strong>structurally related to thionamides</strong> (propylthiouracil and methimazole) and therefore causes hypothyroidism by <strong>preventing organification of iodine</strong> in thyroid hormone synthesis. Another antitubercular&nbsp;drug that can cause hypothyroidism is Para-amino salicylic acid (PAS).&nbsp;</p>\n<p>ETH/PAS-induced hypothyroidism should be treated with <strong>thyroxine replacement therapy</strong>, instead of changing the regimen. Thyroid function usually optimizes within 2 months after completing MDR therapy.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB5225",
      "difficulty": "medium"
    },
    {
      "text": "What is the mechanism of anti-mycobacterial action of bedaquiline?",
      "choices": [
        {
          "id": 1,
          "text": "Inhibition of mycolic acid synthesis"
        },
        {
          "id": 2,
          "text": "Inhibition of protein synthesis"
        },
        {
          "id": 3,
          "text": "Inhibition of ATP synthase"
        },
        {
          "id": 4,
          "text": "Inhibition of RNA synthesis"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The mechanism of anti-mycobacterial action of bedaquiline is by <strong>inhibition of ATP synthase.</strong></p>\n<p class=\"p1\"><strong>Bedaquiline</strong> is a&nbsp;diarylquinoline that targets the<strong> subunit c </strong>of the ATP synthase of M. tuberculosis. This leads&nbsp;to inhibition of the proton pump activity of the ATP synthase and causes a failure in the bacillary energy metabolism.</p><p><strong>Pretomanid&nbsp;</strong>in combination with <strong>bedaquiline </strong>and<strong> linezolid</strong> was approved by FDA in 2019 for the treatment of adult patients with extensively drug-resistant<strong> (XDR) TB </strong>and for patients who are<strong>&nbsp;treatment</strong>-<strong>intolerant or nonresponsive</strong> to multidrug-resistant pulmonary (<strong>MDR</strong>) <strong>TB</strong> treatment.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB5207",
      "difficulty": "easy"
    },
    {
      "text": "A 68-year-old man with hypertension was diagnosed with drug-resistant pulmonary TB. One week after starting ATT he presented to the casualty following an episode of syncope. ECG showed a corrected QT interval of 477ms, which is shown below. Which drug used in his anti-tubercular therapy is responsible for this adverse effect?",
      "choices": [
        {
          "id": 1,
          "text": "Clofazimine"
        },
        {
          "id": 2,
          "text": "Isoniazid"
        },
        {
          "id": 3,
          "text": "Bedaquiline"
        },
        {
          "id": 4,
          "text": "Para-amino salicylic acid"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The given clinical scenario along with a corrected QT (QTc) interval of 477ms is suggestive of&nbsp;<strong>QTc prolongation</strong> which is an adverse effect associated with <strong>bedaquiline.</strong></p>\n<p>In the ECG&nbsp;<strong>QTc&nbsp;</strong>(corrected QT interval= QT/&radic;RR) is&nbsp;<strong>477ms</strong>. Normal QTc is about 440ms. Values of<strong> more than</strong> <strong>440ms in males</strong> and <strong>460ms in females</strong> are considered to be prolonged.&nbsp;QTc prolongation&nbsp;usually presents as <strong>syncope</strong> or <strong>cardiac arrest</strong>.</p>\n<p>Although QT prolongation can cause Torsades de pointes, no cases have been reported with bedaquiline. A 5-fold higher rate of death has been reported in patients on bedaquiline versus those on placebo. Therefore, the World Health Organization (WHO) advises caution when administering this medication. Bedaquiline is <strong>contraindicated</strong> in the age group of <strong>&lt;18 years</strong>.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/9c145c79aefc41c1b540e6ad23c1ebb6.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4122",
      "difficulty": "easy"
    },
    {
      "text": "What is the mechanism of action of delamanid?",
      "choices": [
        {
          "id": 1,
          "text": "Inhibition of ATP synthase"
        },
        {
          "id": 2,
          "text": "Inhibition of mycolic acid synthesis"
        },
        {
          "id": 3,
          "text": "Inhibition of DNA gyrase"
        },
        {
          "id": 4,
          "text": "Inhibition of alanine racemase"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Delamanid</strong>&nbsp;acts by<strong>&nbsp;inhibiting mycolic acid synthesis</strong>.</p>\n<p>Pretomanid and delamanid are bicyclic nitroimidazoles that act by&nbsp;<strong>inhibiting mycolic acid</strong>&nbsp;(a component of the mycobacterial cell wall) and&nbsp;<strong>protein synthesis</strong>&nbsp;in the mycobacteria.</p>\n<p><strong>Pretomanid&nbsp;</strong>in combination with&nbsp;<strong>bedaquiline&nbsp;</strong>and<strong>&nbsp;linezolid</strong>&nbsp;was approved by FDA in 2019 for the treatment of adult patients with extensively drug-resistant<strong>&nbsp;(XDR) TB&nbsp;</strong>and for patients who are<strong>&nbsp;treatment</strong>-<strong>intolerant or nonresponsive</strong>&nbsp;to multidrug-resistant pulmonary (<strong>MDR</strong>)&nbsp;<strong>TB</strong>&nbsp;treatment.</p>\n<p>In India, delamanid is only approved for the management of MDR-TB.</p>\n<p><strong>Isoniazid</strong> also acts by inhibiting mycolic acid synthesis.</p>\n<p>Other options:</p>\n<p>Option A:&nbsp;<strong>Bedaquiline</strong>&nbsp;acts by&nbsp;<strong>inhibition of ATP synthase.&nbsp;</strong>It&nbsp;is a&nbsp;diarylquinoline that targets the<strong>&nbsp;subunit c&nbsp;</strong>of the ATP synthase of M. tuberculosis. This leads&nbsp;to inhibition of the proton pump activity of the ATP synthase and causes a failure in the bacillary energy metabolism.</p>\n<p>Option C: <strong>Fluoroquinolones</strong> act by inhibition of <strong>DNA gyrase. </strong>They are used as second-line agents in the treatment of tuberculosis.</p>\n<p>Option D:&nbsp;<strong>Cycloserine</strong>&nbsp;is a D-alanine analogue used as a second-line drug for MDR-TB that acts by&nbsp;<strong>inhibition of alanine racemase.</strong>&nbsp;Alanine racemase converts L-alanine to D-alanine which is needed for the mycobacterial cell wall.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB5209",
      "difficulty": "medium"
    },
    {
      "text": "A 30-year-old pregnant woman was diagnosed with tuberculosis. Which of the following antitubercular drugs should not be used in her?",
      "choices": [
        {
          "id": 1,
          "text": "Isoniazid"
        },
        {
          "id": 2,
          "text": "Streptomycin"
        },
        {
          "id": 3,
          "text": "Rifampicin"
        },
        {
          "id": 4,
          "text": "Ethambutol"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Streptomycin should not be used for the treatment of TB in a pregnant patient as it can cause<strong> hearing loss </strong>in the<strong> newborn.</strong></p>\n<p class=\"p1\">First-line treatment for tuberculosis in pregnancy is done with isoniazid(along with pyridoxine), rifampicin, ethambutol, and pyrazinamide.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB5215",
      "difficulty": "easy"
    },
    {
      "text": "An HIV-positive patient with a CD4 count of 40/mm3 requires prophylaxis against M. avium complex bacteremia. Which of the following drugs would you prefer?",
      "choices": [
        {
          "id": 1,
          "text": "Azithromycin"
        },
        {
          "id": 2,
          "text": "Dapsone"
        },
        {
          "id": 3,
          "text": "Isoniazid"
        },
        {
          "id": 4,
          "text": "Rifabutin"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Azithromycin</strong>&nbsp;1200 mg given once a week,<strong>&nbsp;</strong>is&nbsp;<strong>preferred</strong> for <strong>prophylactic </strong>therapy against bacteremia caused by <em><strong>Mycobacterium</strong>-<strong>avium complex </strong></em>(MAC) in people living with AIDS.<br /><br />Clarithromycin 500 mg twice daily, may also be administered for prophylaxis. <strong>Rifabutin</strong> 300 mg once daily&nbsp;is used for patients who are <strong>intolerant</strong> to macrolides.</p>\n<p>Prophylaxis&nbsp;is indicated when <strong>CD4</strong> counts are<strong> less than 50/mm<sup>3&nbsp;</sup></strong>and should be discontinued once the CD4 count is more than 100/mm<sup>3</sup>.&nbsp;<br /><br /><strong>Dapsone</strong> is used as an alternative agent for prophylaxis of&nbsp;<strong><em>pneumocystis jirovecii</em></strong> infection, whereas <strong>isoniazid</strong> is used for prophylaxis of&nbsp;<strong><em>mycobacterium tuberculosis</em></strong> infection.</p><hr><h3>Related Pearl: Opportunistic Infections/HIV related conditions and ART initiation</h3><table>\n<tbody>\n<tr>\n<td>Clinical scenario</td>\n<td>Action&nbsp;</td>\n</tr>\n<tr>\n<td>Any undiagnosed active infection with fever</td>\n<td>Diagnose and treat first; start Anti-Retroviral Therapy (ART) when stable</td>\n</tr>\n<tr>\n<td>Tuberculosis (TB)</td>\n<td>Start TB treatment first; start ART as soon as possible after 2 weeks and before 2 months. For those with CD4 less than 50/cmm, start ART within 2 weeks Caution is needed for PLHIV with TB meningitis, since immediate ART is associated with more severe adverse events than initiating ART 2 months after the start of TB treatment</td>\n</tr>\n<tr>\n<td>\n<p>Pneumocystis pneumonia (PCP)</p>\n</td>\n<td>Treat PCP first; start ART when PCP treatment is completed</td>\n</tr>\n<tr>\n<td>Invasive fungal diseases: Oesophageal candidiasis, penicilliosis, histoplasmosis</td>\n<td>Start treatment for oesophageal candidiasis first; start ART as soon as the patient can swallow comfortably. Treat penicilliosis, and histoplasmosis first; start ART when the patient is stabilized or opportunistic infection treatment is completed.</td>\n</tr>\n<tr>\n<td>Cryptococcal meningitis</td>\n<td>Treat cryptococcal meningitis. ART initiation should be deferred until there is evidence of sustained clinical response to anti-fungal therapy and after 4 weeks of induction and consolidation treatment with amphotericin B containing regimen.</td>\n</tr>\n<tr>\n<td>Bacterial pneumonia</td>\n<td>Treat pneumonia first; start ART when treatment is completed</td>\n</tr>\n<tr>\n<td>Malaria</td>\n<td>Treat malaria first; start ART when treatment is completed</td>\n</tr>\n<tr>\n<td>Acute diarrhoea which may reduce absorption of ART</td>\n<td>Diagnose the cause and treat diarrhoea first; start ART when diarrhoea is stabilized or controlled</td>\n</tr>\n<tr>\n<td>Non-severe anaemia (Hb&lt; 9 g/dl)</td>\n<td>Start ART if no other causes for anaemia are found (HIV is often the cause of anaemia)&nbsp;</td>\n</tr>\n<tr>\n<td>Skin conditions such as PPE and seborrhoeic dermatitis, psoriasis, HIV-related exfoliative dermatitis</td>\n<td>Start ART (ART may resolve these problems)&nbsp;</td>\n</tr>\n<tr>\n<td>Suspected Mycobacterium Avium Complex (MAC), Cryptosporidiosis and Microsporidiosis</td>\n<td>Start ART (ART may resolve these problems)</td>\n</tr>\n<tr>\n<td>Cytomegalovirus retinitis</td>\n<td>Start treatment for CMV urgently and start ART after 2 weeks of CMV treatment&nbsp;</td>\n</tr>\n<tr>\n<td>Toxoplasmosis</td>\n<td>Treat toxoplasmosis; start ART after 6 weeks of treatment and when the patient is stabilized</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3940",
      "difficulty": "hard"
    },
    {
      "text": "An elderly woman on ART with a CD4 count of 35/μL and a high viral load presents with a 2 week history of cough, fever, and night sweats. She was diagnosed with pulmonary M. avium complex infection. Which of the following is not included in the triple-drug therapy for the management of her condition?",
      "choices": [
        {
          "id": 1,
          "text": "Rifabutin"
        },
        {
          "id": 2,
          "text": "Isoniazid"
        },
        {
          "id": 3,
          "text": "Ethambutol"
        },
        {
          "id": 4,
          "text": "Clarithromycin"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Triple drug therapy for pulmonary Mycobacterium avium complex (MAC) infections does not include <strong>isoniazid</strong>.</p>\n<p>Treatment for pulmonary&nbsp;<strong>MAC</strong>&nbsp;infection is&nbsp;<strong>triple-drug therapy</strong> with:</p>\n<ul>\n<li>A rifamycin, like <strong>rifampicin </strong>or<strong> rifabutin </strong>(In HIV patients on ART, rifabutin is preferred)</li>\n<li><strong>Ethambutol</strong></li>\n<li>A macrolide, like <strong>clarithromycin</strong> or <strong>azithromycin</strong></li>\n</ul>\n<p>MAC infection is an<strong> AIDS-defining opportunistic infection</strong>, occurring predominantly at CD4+ T cell counts of <strong>&lt;50/&mu;L</strong> and high viral load. The <strong>average</strong> CD4+ T cell count at the time of diagnosis is <strong>10/&mu;L.</strong> The most common presentation is disseminated disease with fever, weight loss, and night sweats.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB5271",
      "difficulty": "medium"
    },
    {
      "text": "A patient undergoing treatment for TB developed resistance to rifampicin and isoniazid after 3 months. He can be treated with all the following drugs except __________.",
      "choices": [
        {
          "id": 1,
          "text": "Tobramycin"
        },
        {
          "id": 2,
          "text": "Amikacin"
        },
        {
          "id": 3,
          "text": "Moxifloxacin"
        },
        {
          "id": 4,
          "text": "Ofloxacin"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Tobramycin cannot be used in the treatment of MDR-TB (rifampicin and isoniazid resistant) as it is not&nbsp;considered a second-line antitubercular drug.&nbsp;</p>\n<p>Injectable aminoglycosides like&nbsp;<strong>amikacin</strong>, kanamycin, capreomycin, and fluoroquinolones like <strong>moxifloxacin</strong> and <strong>ofloxacin&nbsp;</strong>are second-line drugs used for treating MDR-TB.</p><hr><h3>Related Pearl: ATT Regimen for TB Patients</h3><p>As per the latest recommendations from <strong>National Tuberculosis Elimination Programme (NTEP)</strong>, treatment of TB is now based primarily on <strong>drug susceptibility testing</strong>. This is irrespective of new cases, previously treated cases or recurrent TB cases. <br />All cases of TB are treated with Drug Sensitive TB Regimen, as long as the patient is sensitive to isoniazid and rifampicin. (<strong>No classification into category I or II</strong>)</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Type of TB Case</strong></td>\n<td><strong>Intensive Phase</strong></td>\n<td><strong>Continuation Phase</strong></td>\n</tr>\n<tr>\n<td>New and previously treated cases (H and R sensitive)</td>\n<td>2 months H R Z E</td>\n<td>4 months H R E</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<h2><strong><span>Classification based on drug resistance. </span></strong></h2>\n<p><span>The<strong> </strong>cases are classified as:</span></p>\n<ul>\n<li><strong>Mono-resistant (MR):</strong> A TB patient, who is resistant to one 1st line anti-TB drug only.</li>\n<li><strong>Poly-Drug Resistant (PDR):</strong> A TB patient, who is resistant to more than one 1st line anti-TB drug, other than Rifampicin and isoniazid. </li>\n<li><strong>Rifampicin Resistant (RR):</strong> A TB patient, who is resistant to <strong>rifampicin</strong> with or without resistance to other drugs. Patients, who have rifampicin resistance, should be managed as if they are an MDR TB case.</li>\n<li><strong>Multi-Drug Resistant (MDR):</strong> A TB patient, who is resistant to <strong>both isoniazid and rifampicin.</strong></li>\n<li><strong>Extensively Drug-Resistant (XDR):</strong> A MDR TB patient who is additionally resistant to a <strong>fluoroquinolone</strong> (ofloxacin, levofloxacin, or moxifloxacin) and at least one additional group A drug (as of 2021, these are bedaquiline and linezolid)</li>\n</ul>\n<h2><strong><span>Standard DR TB regimen</span></strong></h2>\n<table>\n<tbody>\n<tr>\n<td><strong>Regimen class</strong></td>\n<td><strong>Drugs</strong></td>\n<td><strong>Comments</strong></td>\n</tr>\n<tr>\n<td><strong>H mono-resistant/ poly-drug resistant TB regimen</strong></td>\n<td>Lfx R E Z for 6 months</td>\n<td>\n<p>6 months long</p>\n<p>Oral drugs only</p>\n</td>\n</tr>\n<tr>\n<td><strong>BPaLM regime (New MDR regime by WHO)</strong></td>\n<td>Bdq Pa Lzd Mfx for 6 months</td>\n<td>\n<p>6 months long</p>\n</td>\n</tr>\n<tr>\n<td><strong>9- 11 months shorter oral bedaquiline regime (Shorter MDR)</strong></td>\n<td>\n<p><strong>Intensive Phase:</strong></p>\n<p>Lfx Bdq(6 months) Cfz Z Hh E Eto for 4-6 months</p>\n<p><strong>Continuation phase:</strong></p>\n<p>Lfx Cfz Z E for 5 months</p>\n</td>\n<td>\n<p>9-11 months long totally</p>\n<p>Injectables used in Intensive phase.</p>\n</td>\n</tr>\n<tr>\n<td><strong>Longer MDR TB regimen</strong></td>\n<td>Bdq(6 months or longer) Lfx Lzd Cfz Cs </td>\n<td>\n<p>18-20 months long</p>\n<p>Oral drugs only</p>\n<p>This regimen is used for XDR TB patients for 20 months.</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<h2> </h2>\n<h2><strong><span>Criteria for patients to receive standard Drug Resistant TB regimen:</span></strong></h2>\n<table>\n<tbody>\n<tr>\n<td><strong>Standard Drug Resistant TB regimen</strong></td>\n<td><strong>Inclusion criteria</strong></td>\n<td><strong>Exclusion criteria</strong></td>\n</tr>\n<tr>\n<td><strong>H mono-resistant/poly-drug resistant TB regimen</strong></td>\n<td><strong>Isoniazid resistant</strong> TB with <strong>rifampicin sensitive</strong></td>\n<td>No specific criteria</td>\n</tr>\n<tr>\n<td><strong>BPaLM regimen (New MDR TB regimen by WHO)</strong></td>\n<td>\n<ol>\n<li><strong>MDR/RR-TB</strong> or <strong>pre-XDR-TB</strong> ( MDR/RR-TB and resistance to fluoroquinolones). </li>\n<li>Those with <strong>confirmed</strong> pulmonary TB and all forms of extrapulmonary TB (except for TB involving CNS, osteoarticular, and miliary TB).</li>\n<li>Patients <strong>&gt;14 years of age.<br /></strong></li>\n</ol>\n</td>\n<td>Pregnant and lactating women</td>\n</tr>\n<tr>\n<td><strong>9- 11 months shorter MDR TB regimen</strong></td>\n<td>Patient with <strong>rifampicin resistant</strong> pulmonary or extra pulmonary TB</td>\n<td>Non drug sensitivity test based criteria:\n<ul>\n<li>Pregnancy</li>\n<li>Any extra pulmonary disease in PLHIV</li>\n<li>Disseminated meningeal or central nervous system TB</li>\n<li>Intolerance to any drug in the shorter MDR TB regimen</li>\n</ul>\nDrug sensitivity test based criteria:\n<ul>\n<li>If DST/DRT result for FQ or SLI is resistant (XDR TB)</li>\n<li>Presence of InhA mutation</li>\n<li>Resistant to Z </li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Longer MDR TB regimen</strong></td>\n<td>Patients in whom <strong>shorter MDR TB regimen cannot be considered</strong> due to any reason</td>\n<td>None</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Legend</p>\n<p>FQ: Fluoroquinolone</p>\n<p>SLI: Second Line Injectable</p>\n<p>PLHIV: People Living with HIV</p>\n<p>Lfx: Levofloxacin</p>\n<p>Pa: Pretomanid</p>\n<p>H: Isoniazid</p>\n<p>Hh: High Dose Isoniazid</p>\n<p>R: Rifampicin</p>\n<p>E: Ethambutol</p>\n<p>Z: Pyrazinamide</p>\n<p>Mfx: Moxifloxacin</p>\n<p>Km: Kanamycin</p>\n<p>Am: Amikacin</p>\n<p>Eto: Ethionamide</p>\n<p>Cfz: Clofazimine</p>\n<p>Bdq: Bedaquiline</p>\n<p>Lzd: Linezolid</p>\n<p>Cs: Cycloserine</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB5246",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following beta lactam class has shown activity against MDR-TB?",
      "choices": [
        {
          "id": 1,
          "text": "Aminopenicillins"
        },
        {
          "id": 2,
          "text": "Monobactams"
        },
        {
          "id": 3,
          "text": "Carboxypenicllins"
        },
        {
          "id": 4,
          "text": "Carbapenems"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Carbapenems </strong>have shown activity against <em>Mycobacterium tuberculosis</em>.</p>\n<p>Note: Until recently beta-lactams were assumed to lack action against <em>Mycobacterium tuberculosis. </em>However,<em>&nbsp;</em><strong>carbapenems in conjunction with clavulanate</strong> have demosntrated efficacy&nbsp;against <em>Mycobacterium tuberculosis.</em></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3938",
      "difficulty": "medium"
    }
  ]
}